- Others
The factors impacting the growth of the market are the rise in the trend of self-medication and increased awareness of GERD. Moreover, the constant occurrence of GERD disorders, as well as changes in lifestyle, is propelling the market demand. The expiration of the patent on most of the drugs is paving the way for new over the counter and generic drugs. The poor reimbursement of procedures and devices, low safety, and efficacy are restricting the adoption of the GERD drugs and devices market.
ORDER NOW (Customized Report Delivered as per Your Specific Requirement)@ https://www.emergenresearch.com/request-for-customization-form/383
E-Mail
Skokie, IL - The ISSCR is bringing together successful biotech CEOs who have transformed scientific breakthroughs into thriving businesses that are improving human health into one program 7-8 January 2021.
VISION2030 comes at a pivotal moment in regenerative medicine and stem cell science as discovery, translation, and investment intersect.
Thursday, 7 January
STEMCELL Technologies Executive Interview
Interviewed by ISSCR Board Member Valentina Greco, Yale University School of Medicine, USA
STEMCELL Technologies mission is to advance the pursuit of scientific knowledge by supplying high quality, innovative reagents, tools, and services that enable life science research.
Surrozen Executive Interview
Claudia Janda, Princes Máxima Centrum, Netherlands l Surrozen Founder
- Others
The factors impacting the growth of the market are the rise in the trend of self-medication and increased awareness of GERD. Moreover, the constant occurrence of GERD disorders, as well as changes in lifestyle, is propelling the market demand. The expiration of the patent on most of the drugs is paving the way for new over the counter and generic drugs. The poor reimbursement of procedures and devices, low safety, and efficacy are restricting the adoption of the GERD drugs and devices market.
ORDER NOW (Customized Report Delivered as per Your Specific Requirement)@ https://www.emergenresearch.com/request-for-customization-form/383
Published: Dec 21, 2020
ALAMEDA, Calif. (BUSINESS WIRE) Exelixis, Inc. (NASDAQ: EXEL) today announced that COSMIC-311, the phase 3 pivotal trial evaluating cabozantinib (CABOMETYX
®) versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after up to two prior vascular endothelial growth factor receptor (VEGFR)-targeted therapies, met the co-primary endpoint of demonstrating significant improvement in progression-free survival. Cabozantinib reduced the risk of disease progression or death by 78% with a hazard ratio of 0.22 (96% CI 0.13 – 0.36; p
Dec 21, 2020 07:00 UTC
Takeda Furthers Innovation-Focused Strategy in China with Sale of Select Non-Core Assets to Hasten for $322 million USD OSAKA, Japan (Business Wire) Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of non-core prescription pharmaceutical products sold in China to Hasten Biopharmaceutic Co., Ltd. (China) (“Hasten”), a company funded by Feidong County of Hefei City, China and established by Ray Capital Management Limited (“Ray Capital”)
1 Takeda will receive $322 million USD, subject to customary legal and regulatory closing conditions.
The portfolio to be divested to Hasten includes cardiovascular and metabolism products sold in mainland China. The portfolio generated FY2019 net sales of approximately $109.5 million USD, driven by strong sales of cardiovascular products such as Ebrantil